Tom Wilkinson - Concepedia

Author

Tom Wilkinson

Also Known As

A. C. Tuck, Jorgen Vestbo, Karl J. Staples, T M A Wilkinson, T M Wilkinson, T Wilkinson, T. M. A. Wilkinson, T. M. Wilkinson, T. Wilkinson, T.M Wilkinson

418

Publications

14.7K

Citations

H-Index

101

Concepts

All Affiliations

University of Southampton University Hospital Southampton NHS Foundation Trust Southampton General Hospital NIHR Southampton Biomedical Research Centre NIHR Southampton Respiratory Biomedical Research Unit

About

Tom Wilkinson is an author at University of Southampton specializing in medicine, pulmonary medicine, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	37	6K
2	Allergy	12	12	1.8K
3	Health Sciences	7	7	165
4	Public Health	2	2	332
5	Allergy Medicine	1	1	37

Tom Wilkinson

116

Publications

12.3K

Citations

H-Index

Page 1

	Year	Citations
Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans Tom Wilkinson, Chris Ka‐fai Li, Cecilia Chui, Nature Medicine VaccinationAdaptive Immune SystemImmunologyInfluenza ChallengeT Cell Immunity	2012	997
Early Therapy Improves Outcomes of Exacerbations of Chronic Obstructive Pulmonary Disease Tom Wilkinson, Gavin C. Donaldson, John R. Hurst, American Journal of Respiratory and Critical Care Medicine AsthmaInflammatory Lung DiseaseAdvanced Lung DiseaseHealth-related QualityClinical Epidemiology	2004	694
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults Ben Killingley, Alex Mann, Mariya Kalinova, Nature Medicine Young AdultsViral PersistenceViral KineticsCovid-19 PandemicImmunology	2022	511
Bronchiectasis, Exacerbation Indices, and Inflammation in Chronic Obstructive Pulmonary Disease Irem Patel, Ioannis Vlahos, Tom Wilkinson, American Journal of Respiratory and Critical Care Medicine AsthmaInflammatory Lung DiseaseAdvanced Lung DiseaseLung InflammationImmunology	2004	459
Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease John R. Hurst, Gavin C. Donaldson, Wayomi R. Perera, American Journal of Respiratory and Critical Care Medicine	2006	457
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial Phillip Monk, Richard Marsden, Victoria Tear, The Lancet Respiratory Medicine Sars-cov-2 InfectionCovid-19 PandemicImmunologyAntiviral TherapyRespiratory Infection	2020	448
Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease Exacerbations Terence Seemungal, Tom Wilkinson, John R. Hurst, American Journal of Respiratory and Critical Care Medicine	2008	438
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus John P. DeVincenzo, Rob Lambkin‐Williams, Tom Wilkinson, Proceedings of the National Academy of Sciences Rsv AntibodyRespiratory Syncytial VirusRnai-based TherapyAllergyViral Replication	2010	434
Inflammatory changes, recovery and recurrence at COPD exacerbation Wayomi R. Perera, John R. Hurst, Tom Wilkinson, European Respiratory Journal InflammationRecurrent ExacerbationAllergyInflammatory Lung DiseaseLung Inflammation	2006	365
Airway Bacterial Load and FEV <sub>1</sub> Decline in Patients with Chronic Obstructive Pulmonary Disease Tom Wilkinson, Irem Patel, Mark Wilks, American Journal of Respiratory and Critical Care Medicine	2003	356

Page 1